Defining Key Signaling Nodes and Therapeutic Biomarkers in <i>NF1</i> -Mutant Cancers

Abstract excerpt

UNLABELLED: NF1 encodes a RAS GTPase-activating protein. Accordingly, aberrant RAS activation underlies the pathogenesis of NF1-mutant cancers. Nevertheless, it is unclear which RAS pathway components represent optimal therapeutic targets. Here, we identify mTORC1 as the key PI3K effector in NF1-mutant nervous system malignancies and conversely show that mTORC2 and AKT are dispensable. However, we find that tumor...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neurofibromatosis and Schwannoma Cases
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Tuberous Sclerosis Complex Research